Ausgabe 2/2019
Inhalt (14 Artikel)
Toll-like receptor/interleukin-1 domain innate immune signalling pathway genetic variants are candidate predictors for severe gastrointestinal toxicity risk following 5-fluorouracil-based chemotherapy
Samantha K. Korver, Rachel J. Gibson, Joanne M. Bowen, Janet K. Coller
6-MOMIPP, a novel brain-penetrant anti-mitotic indolyl-chalcone, inhibits glioblastoma growth and viability
Shengnan Du, Jeffrey G. Sarver, Christopher J. Trabbic, Paul W. Erhardt, Allen Schroering, William A. Maltese
Role of the HDAC6/STAT3 pathway in regulating PD-L1 expression in osteosarcoma cell lines
Ajimu Keremu, Abudusaimi Aimaiti, Zhilin Liang, Xiaoguang Zou
Pharmacokinetics of liposomal curcumin (Lipocurc™) infusion: effect of co-medication in cancer patients and comparison with healthy individuals
Gordon T. Bolger, Albert Licollari, Amin Tan, Richard Greil, Brigitta Vcelar, Sigrun Greil-Ressler, Lukas Weiss, Charlotte Schönlieb, Teresa Magnes, Bianca Radl, Muhammed Majeed, Peter P. Sordillo
Knockdown of long non-coding HOTAIR enhances the sensitivity to progesterone in endometrial cancer by epigenetic regulation of progesterone receptor isoform B
Shuqi Chi, Yan Liu, Xing Zhou, Dilu Feng, Xianjin Xiao, Wenliang Li, Yingchao Zhao, Hongbo Wang
A phase I study of single-agent BEZ235 special delivery system sachet in Japanese patients with advanced solid tumors
Masanori Toyoda, Koichiro Watanabe, Taro Amagasaki, Kazuto Natsume, Hiromi Takeuchi, Cornelia Quadt, Kuniaki Shirao, Hironobu Minami
Metastatic or locally advanced breast cancer patients: towards an expert consensus on nab-paclitaxel treatment in HER2-negative tumours—the MACBETH project
Marina E. Cazzaniga, E. Ciruelos, A. Fabi, J. Garcia-Saenz, H. Lindman, D. Mavroudis, C. Schem, G. Steger, E. Timotheadou, K. Zaman, V. Torri
Population pharmacokinetics and exposure–response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias
Renu Singh, Shailly Mehrotra, Mathangi Gopalakrishnan, Ivana Gojo, Judith E. Karp, Jacqueline M. Greer, Alice Chen, Richard Piekarz, Brian F. Kiesel, Jogarao Gobburu, Michelle A. Rudek, Jan H. Beumer
Population pharmacokinetic and covariate analyses of intravenous trastuzumab (Herceptin®), a HER2-targeted monoclonal antibody, in patients with a variety of solid tumors
Angelica L. Quartino, Hanbin Li, Whitney P. Kirschbrown, Ranvir Mangat, D. Russell Wada, Amit Garg, Jin Y. Jin, Bert Lum
Prevalence of TPMT, ITPA and NUDT 15 genetic polymorphisms and their relation to 6MP toxicity in north Indian children with acute lymphoblastic leukemia
Sanjeev Khera, Amita Trehan, Prateek Bhatia, Minu Singh, Deepak Bansal, Neelam Varma
A prospective study of a simple algorithm to individually dose high-dose methotrexate for children with leukemia at risk for methotrexate toxicities
Jennifer H. Foster, Patrick A. Thompson, M. Brooke Bernhardt, Judith F. Margolin, Susan G. Hilsenbeck, Eunji Jo, Deborah A. Marquez-Do, Michael E. Scheurer, Eric S. Schafer
Murine RAW264.7 cells as cellular drug delivery carriers for tumor therapy: a good idea?
Huangliang Zheng, Jiaqi Li, Xiang Luo, Cong LI, Ling Hu, Qiujun Qiu, Junqiang Ding, Yanzhi Song, Yihui Deng
Octreotide SC depot in patients with acromegaly and functioning neuroendocrine tumors: a phase 2, multicenter study
Marianne Pavel, Françoise Borson-Chazot, Anne Cailleux, Dieter Hörsch, Harald Lahner, Rosario Pivonello, Libuse Tauchmanova, Christelle Darstein, Håkan Olsson, Fredrik Tiberg, Diego Ferone
Gemcitabine and metabolite pharmacokinetics in advanced NSCLC patients after bronchial artery infusion and intravenous infusion
Abeer F. Alharbi, Robert A. Kratzke, Jonathan D’Cunha, Michael Anthony Maddaus, Kinjal Sanghavi, Mark N. Kirstein